Cargando…
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
Ospemifene—a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013—is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vag...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Menopause
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606913/ https://www.ncbi.nlm.nih.gov/pubmed/28951854 http://dx.doi.org/10.6118/jmm.2017.23.2.79 |